Elucidating novel mechanisms of brain injury following subarachnoid hemorrhage: An emerging role for neuroproteomics

Melanie D. King, Melissa D. Laird, Sangeetha Sukumari Ramesh, Patrick Youssef, Basheer Shakir, John R. Vender, Cargill H. Alleyne, Krishnan M. Dhandapani

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

Subarachnoid hemorrhage (SAH) is a devastating neurological injury associated with significant patient morbidity and death. Since the first demonstration of cerebral vasospasm nearly 60 years ago, the preponderance of research has focused on strategies to limit arterial narrowing and delayed cerebral ischemia following SAH. However, recent clinical and preclinical data indicate a functional dissociation between cerebral vasospasm and neurological outcome, signaling the need for a paradigm shift in the study of brain injury following SAH. Early brain injury may contribute to poor outcome and early death following SAH. However, elucidation of the complex cellular mechanisms underlying early brain injury remains a major challenge. The advent of modern neuroproteomics has rapidly advanced scientific discovery by allowing proteome-wide screening in an objective, nonbiased manner, providing novel mechanisms of brain physiology and injury. In the context of neurosurgery, proteomic analysis of patientderived CSF will permit the identification of biomarkers and/or novel drug targets that may not be intuitively linked with any particular disease. In the present report, the authors discuss the utility of neuroproteomics with a focus on the roles for this technology in understanding SAH. The authors also provide data from our laboratory that identifies high-mobility group box protein-1 as a potential biomarker of neurological outcome following SAH in humans.

Original languageEnglish (US)
Pages (from-to)E10.1-E10.10
JournalNeurosurgical focus
Volume28
Issue number1
DOIs
StatePublished - May 7 2010

Fingerprint

Subarachnoid Hemorrhage
Brain Injuries
Intracranial Vasospasm
Biomarkers
HMGB1 Protein
Neurosurgery
Proteome
Brain Ischemia
Proteomics
Technology
Morbidity
Wounds and Injuries
Research
Pharmaceutical Preparations

Keywords

  • Biomarker
  • Cerebral aneurysm
  • Cerebrospinal fluid
  • Early brain injury
  • Hemorrhagic stroke
  • Inflammation

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Elucidating novel mechanisms of brain injury following subarachnoid hemorrhage : An emerging role for neuroproteomics. / King, Melanie D.; Laird, Melissa D.; Ramesh, Sangeetha Sukumari; Youssef, Patrick; Shakir, Basheer; Vender, John R.; Alleyne, Cargill H.; Dhandapani, Krishnan M.

In: Neurosurgical focus, Vol. 28, No. 1, 07.05.2010, p. E10.1-E10.10.

Research output: Contribution to journalReview article

King, Melanie D. ; Laird, Melissa D. ; Ramesh, Sangeetha Sukumari ; Youssef, Patrick ; Shakir, Basheer ; Vender, John R. ; Alleyne, Cargill H. ; Dhandapani, Krishnan M. / Elucidating novel mechanisms of brain injury following subarachnoid hemorrhage : An emerging role for neuroproteomics. In: Neurosurgical focus. 2010 ; Vol. 28, No. 1. pp. E10.1-E10.10.
@article{df5a61d76e0d482ba9581f47819d39b8,
title = "Elucidating novel mechanisms of brain injury following subarachnoid hemorrhage: An emerging role for neuroproteomics",
abstract = "Subarachnoid hemorrhage (SAH) is a devastating neurological injury associated with significant patient morbidity and death. Since the first demonstration of cerebral vasospasm nearly 60 years ago, the preponderance of research has focused on strategies to limit arterial narrowing and delayed cerebral ischemia following SAH. However, recent clinical and preclinical data indicate a functional dissociation between cerebral vasospasm and neurological outcome, signaling the need for a paradigm shift in the study of brain injury following SAH. Early brain injury may contribute to poor outcome and early death following SAH. However, elucidation of the complex cellular mechanisms underlying early brain injury remains a major challenge. The advent of modern neuroproteomics has rapidly advanced scientific discovery by allowing proteome-wide screening in an objective, nonbiased manner, providing novel mechanisms of brain physiology and injury. In the context of neurosurgery, proteomic analysis of patientderived CSF will permit the identification of biomarkers and/or novel drug targets that may not be intuitively linked with any particular disease. In the present report, the authors discuss the utility of neuroproteomics with a focus on the roles for this technology in understanding SAH. The authors also provide data from our laboratory that identifies high-mobility group box protein-1 as a potential biomarker of neurological outcome following SAH in humans.",
keywords = "Biomarker, Cerebral aneurysm, Cerebrospinal fluid, Early brain injury, Hemorrhagic stroke, Inflammation",
author = "King, {Melanie D.} and Laird, {Melissa D.} and Ramesh, {Sangeetha Sukumari} and Patrick Youssef and Basheer Shakir and Vender, {John R.} and Alleyne, {Cargill H.} and Dhandapani, {Krishnan M.}",
year = "2010",
month = "5",
day = "7",
doi = "10.3171/2009.10.FOCUS09223",
language = "English (US)",
volume = "28",
pages = "E10.1--E10.10",
journal = "Neurosurgical Focus",
issn = "1092-0684",
publisher = "American Association of Neurological Surgeons",
number = "1",

}

TY - JOUR

T1 - Elucidating novel mechanisms of brain injury following subarachnoid hemorrhage

T2 - An emerging role for neuroproteomics

AU - King, Melanie D.

AU - Laird, Melissa D.

AU - Ramesh, Sangeetha Sukumari

AU - Youssef, Patrick

AU - Shakir, Basheer

AU - Vender, John R.

AU - Alleyne, Cargill H.

AU - Dhandapani, Krishnan M.

PY - 2010/5/7

Y1 - 2010/5/7

N2 - Subarachnoid hemorrhage (SAH) is a devastating neurological injury associated with significant patient morbidity and death. Since the first demonstration of cerebral vasospasm nearly 60 years ago, the preponderance of research has focused on strategies to limit arterial narrowing and delayed cerebral ischemia following SAH. However, recent clinical and preclinical data indicate a functional dissociation between cerebral vasospasm and neurological outcome, signaling the need for a paradigm shift in the study of brain injury following SAH. Early brain injury may contribute to poor outcome and early death following SAH. However, elucidation of the complex cellular mechanisms underlying early brain injury remains a major challenge. The advent of modern neuroproteomics has rapidly advanced scientific discovery by allowing proteome-wide screening in an objective, nonbiased manner, providing novel mechanisms of brain physiology and injury. In the context of neurosurgery, proteomic analysis of patientderived CSF will permit the identification of biomarkers and/or novel drug targets that may not be intuitively linked with any particular disease. In the present report, the authors discuss the utility of neuroproteomics with a focus on the roles for this technology in understanding SAH. The authors also provide data from our laboratory that identifies high-mobility group box protein-1 as a potential biomarker of neurological outcome following SAH in humans.

AB - Subarachnoid hemorrhage (SAH) is a devastating neurological injury associated with significant patient morbidity and death. Since the first demonstration of cerebral vasospasm nearly 60 years ago, the preponderance of research has focused on strategies to limit arterial narrowing and delayed cerebral ischemia following SAH. However, recent clinical and preclinical data indicate a functional dissociation between cerebral vasospasm and neurological outcome, signaling the need for a paradigm shift in the study of brain injury following SAH. Early brain injury may contribute to poor outcome and early death following SAH. However, elucidation of the complex cellular mechanisms underlying early brain injury remains a major challenge. The advent of modern neuroproteomics has rapidly advanced scientific discovery by allowing proteome-wide screening in an objective, nonbiased manner, providing novel mechanisms of brain physiology and injury. In the context of neurosurgery, proteomic analysis of patientderived CSF will permit the identification of biomarkers and/or novel drug targets that may not be intuitively linked with any particular disease. In the present report, the authors discuss the utility of neuroproteomics with a focus on the roles for this technology in understanding SAH. The authors also provide data from our laboratory that identifies high-mobility group box protein-1 as a potential biomarker of neurological outcome following SAH in humans.

KW - Biomarker

KW - Cerebral aneurysm

KW - Cerebrospinal fluid

KW - Early brain injury

KW - Hemorrhagic stroke

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=76549110388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76549110388&partnerID=8YFLogxK

U2 - 10.3171/2009.10.FOCUS09223

DO - 10.3171/2009.10.FOCUS09223

M3 - Review article

C2 - 20043714

AN - SCOPUS:76549110388

VL - 28

SP - E10.1-E10.10

JO - Neurosurgical Focus

JF - Neurosurgical Focus

SN - 1092-0684

IS - 1

ER -